What causes serum sickness?

Serum sickness is caused by a foreign protein, or less often a drug, that stays in the blood long enough for the body to make antibodies against it. Classic triggers are animal-derived antisera such as antivenoms and horse or rabbit antithymocyte globulin, chimeric monoclonal antibodies such as rituximab and infliximab, and some drugs, including beta-lactam and sulfonamide antibiotics. Older antivenin preparations caused it in about half of patients; modern fragment antivenoms cause it far less often.

How long after exposure does serum sickness start?

Symptoms usually begin 1 to 2 weeks after the first exposure, the time it takes to make IgG antibodies against the foreign protein; reported onsets range from about 6 to 21 days. In someone sensitized by an earlier exposure, symptoms can start within 1 to 7 days. A reaction within minutes suggests IgE-mediated anaphylaxis, and painful swelling at an injection site within hours suggests a local Arthus reaction.

Is serum sickness a type III or type IV hypersensitivity reaction?

Serum sickness is a type III reaction. Antigen-antibody complexes form while foreign antigen is still in excess, deposit in small vessels, joints and glomeruli, and activate the classical complement pathway, which recruits neutrophils that damage vessel walls. Type IV reactions are driven by T cells rather than antibodies, as in contact dermatitis, the tuberculin skin test, DRESS and Stevens-Johnson syndrome. Low C3 and C4 reflect complement consumption, a type III feature that type IV reactions lack.

Why are C3 and C4 low in serum sickness?

Deposited immune complexes activate the classical complement pathway, which uses up C4 and C3 faster than the liver can replace them, so serum C3, C4 and total hemolytic complement (CH50) fall during active disease. In a classic prospective study of patients given horse antithymocyte globulin, C3 and C4 reached their lowest levels on day 10, around the time circulating immune complexes peaked. Activation also releases C3a and C5a, which increase vascular permeability and attract neutrophils.

What is the difference between serum sickness and a serum sickness-like reaction?

Both cause rash, joint pain and often fever after exposure to a trigger, but a serum sickness-like reaction has no circulating immune complexes. Complement stays normal, lymphadenopathy and proteinuria are infrequent, and the kidneys are spared. Serum sickness-like reactions follow drugs, classically cefaclor in children, often during or after a second course, as well as penicillins, other cephalosporins and sulfonamides. True serum sickness follows foreign proteins such as antivenom or antithymocyte globulin.

How is serum sickness treated, and how long does it last?

Stop the offending agent and avoid it in the future, because a re-exposure can cause a faster and more severe reaction. Antihistamines relieve itching and hives, and NSAIDs treat joint pain and fever. Severe or multi-organ disease is treated with a short course of systemic glucocorticoids. Epinephrine is only for anaphylaxis, not for this delayed reaction. Most cases resolve within 1 to 2 weeks after the trigger is stopped, without lasting damage.

Serum Sickness (Type III): Triad, Timing & Low C3/C4

Serum sickness is a systemic type III (immune complex) hypersensitivity reaction to a foreign protein or, less often, a drug. About 1–2 weeks after a first exposure (1–7 days after a re-exposure), IgG antibodies meet antigen that is still circulating; the immune complexes deposit in small vessels, joints and glomeruli and activate the classical complement pathway. The result is the classic triad of fever, rash (classically urticarial) and polyarthralgia, with low C3, C4 and CH50, sometimes with lymphadenopathy or mild proteinuria. Classic triggers are antivenoms, antithymocyte globulin and chimeric antibodies such as rituximab and infliximab; stopping the trigger is the key treatment, and most cases resolve within 1–2 weeks.

Serum sickness at a glance

Feature	What to know
Hypersensitivity type	Type III, systemic: circulating antigen–antibody complexes deposit in vessel walls and fix complement
Timing	1–2 weeks after a first exposure (reported range about 6–21 days); 1–7 days after a re-exposure
Classic triad	Fever, rash, polyarthralgia (frank arthritis is less common)
Rash	Urticarial, morbilliform or purpuric; may start at the injection site; serpiginous red-purple eruption along the edges of the palms and soles; mucous membranes spared
Other findings	Malaise, GI upset; less often edema, lymphadenopathy, splenomegaly, uveitis, neuropathy, vasculitis or kidney injury
Labs	Low C3, C4 and CH50; raised ESR and CRP; mild proteinuria
Triggers	Animal-derived antisera (antivenoms, antitoxins, horse or rabbit antithymocyte globulin); chimeric monoclonal antibodies (rituximab, infliximab); some drugs
Treatment	Stop the agent; H1 antihistamines and NSAIDs; systemic glucocorticoids if severe
Course	Self-limited; usually resolves within 1–2 weeks of stopping the agent

How immune complexes cause serum sickness

A large load of foreign antigen circulates for days: horse, sheep or rabbit immunoglobulin, a mouse-derived antibody region, or a drug acting as a hapten on a carrier protein.
Antibodies arrive after about 6–10 days, which explains the 1–2-week delay; a sensitized patient responds within days.
Antigen excess makes small, soluble complexes. Macrophages clear large complexes efficiently but not small ones, which keep circulating; the complexes that deposit are mainly medium-sized.
Complexes lodge in vessel walls, especially in the skin, synovium and glomeruli.
The classical pathway fires. C1q binds the complexed IgG, and C4, C2 and C3 are consumed. C3a and C5a raise vascular permeability and recruit neutrophils and monocytes, whose proteolytic enzymes and reactive oxygen species damage the vessel; platelets form microthrombi. Skin biopsy typically shows leukocytoclastic vasculitis.
The reaction burns out. Once the foreign antigen is cleared, new complexes stop forming.

The classic time course comes from a prospective NIH study of 12 patients given horse antithymocyte globulin for bone marrow failure: 11 developed serum sickness 8–13 days after starting therapy, circulating immune complexes peaked at days 10–12, C4 and C3 fell precipitously with nadirs on day 10, and plasma C3a was raised in all four patients tested. For the pathway itself, see classical vs lectin vs alternative complement.

Timing: first exposure vs re-exposure

Timing is the first clue to the mechanism:

Onset after exposure	Think of
Minutes	Type I: anaphylaxis, acute urticaria
Hours, at an injection site (peak by about 24 hours)	Arthus reaction (local type III)
48–72 hours	Type IV: contact dermatitis, tuberculin skin test
1–7 days after a re-exposure	Serum sickness in a sensitized patient
A few days into a drug course, often the second	Cefaclor serum sickness–like reaction
7–14 days after a first exposure (range about 6–21)	Serum sickness (time to make IgG)
2–8 weeks after a new drug	DRESS

The data agree: onset was 8–13 days in the 1984 NIH cohort, and in a second NIH series the rash began on day 7 ± 1 and lasted 12 ± 2 days. Merck places drug-induced serum sickness at 7–10 days and serum sickness after the ovine Fab antivenom at 1–3 weeks. In infliximab psoriasis trials, possible delayed hypersensitivity reactions generally appeared within 2 weeks of a repeat infusion; the label also reports serum sickness–like reactions as early as the second dose and when infliximab is restarted after a long drug-free period.

Triggers and how often they cause it

These rates come from different doses, settings and follow-up methods, so compare them loosely.

Trigger	Examples	What the sources report
Older antivenin preparations	Antivenins in use before the ovine Fab product	Serum sickness in 44–61%
Ovine Fab antivenom	Crotalidae polyvalent immune Fab (sheep IgG fragments) for pit viper bites	About 13% (StatPearls); up to 16%, 1–3 weeks after treatment (Merck)
Equine F(ab')₂ antivenom	Horse IgG fragments for scorpion stings; a similar product treats North American pit viper bites, including rattlesnakes	Symptoms suggestive of serum sickness in 8 of 1,534 (0.5%) scorpion-antivenom trial patients; none had the full syndrome
Horse antithymocyte globulin	ATGAM, for aplastic anemia and kidney transplant rejection	11 of 12 and 30 of 35 in NIH bone marrow failure cohorts
Chimeric monoclonal antibodies	Infliximab (anti-TNF), rituximab (anti-CD20)	Infliximab: serum sickness or serum sickness–like symptoms in about 1% (15 of 1,373) of psoriasis trial patients; rituximab: higher risk with hypergammaglobulinemia or hepatitis C–related cryoglobulinemic vasculitis
Drugs	Beta-lactam and sulfonamide antibiotics, iron dextran, carbamazepine	The drugs Merck lists as most often implicated
Vaccines	Human diploid cell rabies vaccine	Reported

Fragments help. Modern antivenoms are purified antibody fragments without the Fc portion: Fab (papain digestion) or F(ab')₂ (pepsin digestion). Their reported rates are far below the 44–61% reported with older antivenins.
Chimeric antibodies are immunogenic. Infliximab is a chimeric IgG1κ antibody with human constant and murine variable regions, and rituximab is chimeric too. The infliximab label ties its serum sickness–like reactions to a marked rise in antibodies to infliximab and loss of detectable drug levels.
Skin testing doesn't predict it. A negative skin test to an antiserum does not predict whether serum sickness will follow.
For other drug reactions sorted by mechanism, see drug hypersensitivity examples.

Serum sickness–like reaction (SSLR)

A serum sickness–like reaction looks the same at the bedside (rash, joint pain, often fever) but has no circulating immune complexes and normal complement. The usual culprits are penicillins (such as amoxicillin), cephalosporins (most commonly cefaclor), sulfonamides, bupropion, fluoxetine and thiouracil.

The cefaclor label is the classic description:

Erythema multiforme, rashes and other skin findings with arthritis or arthralgia, with or without fever; lymphadenopathy and proteinuria are infrequent, there are no circulating immune complexes, and no sequelae have been reported.
Onset a few days after starting the drug, more often during or after a second (or later) course; symptoms subside within a few days of stopping it.
Reported more often in children than in adults. Overall occurrence ranged from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) across clinical trials (0.055% in children in those trials) and 1 in 38,000 (0.003%) in spontaneous reports.
Antihistamines and glucocorticoids appear to speed resolution.

Feature	True serum sickness	Serum sickness–like reaction
Typical trigger	Foreign proteins: antivenoms, antithymocyte globulin, chimeric antibodies	Drugs: cefaclor, other beta-lactams, sulfonamides
Who	More common in adults	Cefaclor reactions more common in children
Circulating immune complexes	Present	Absent
C3, C4, CH50	Low	Normal
Lymphadenopathy, proteinuria	Can occur	Infrequent
Kidney involvement	Possible (proteinuria, transient creatinine rise)	Not expected

Exam rule: low complement, immune complexes, vasculitis or kidney findings mean true type III serum sickness, which drugs can also cause (Merck classifies drug serum sickness as type III, from medication–antibody complexes). A child on cefaclor with hives, swollen joints and normal C3 and C4 has an SSLR.

Clinical features: the triad and beyond

Classic prospective data come from NIH patients given horse antithymocyte globulin for bone marrow failure; of 35 patients, 30 developed serum sickness:

Finding	Frequency in the 30 patients
Fever and malaise	100%
Rash	93% (morbilliform 19, urticaria 1, both 8)
Arthralgias and myalgias	67%
Gastrointestinal complaints	67%
Lymphadenopathy	13%

Fever: fever with malaise was present in all 30 NIH patients, the most consistent finding in that series.
Rash: classically urticarial and itchy, but morbilliform and purpuric (vasculitic) eruptions are common; morbilliform rashes predominated after antithymocyte globulin. The rash may first appear around an injection site. Mucous membranes are spared, unlike Stevens–Johnson syndrome and toxic epidermal necrolysis.
The hands-and-feet sign: in the 1984 NIH study, 8 of 11 patients with serum sickness had a serpiginous erythematous and purpuric eruption on the hands and feet at the junction of palmar and plantar skin. In the larger series, 21 of 28 patients with a rash developed erythema along the sides of the fingers, toes, palms and soles 12–48 hours before the morbilliform rash.
Joints: arthralgias are more common than frank arthritis; the hands, feet, ankles, knees and shoulders are most often affected.
Less common: edema of the face, hands and feet, headache, blurred vision, splenomegaly, anterior uveitis, peripheral neuropathy, nephropathy or vasculitis.

Labs and diagnosis

Diagnosis is clinical: the right exposure 1–2 weeks earlier plus fever, rash and joint symptoms. Tests confirm complement consumption, check for organ involvement and exclude mimics.

Test	Expected in serum sickness
C3 and C4	Low (classical-pathway consumption; nadir around day 10 in the NIH cohort)
CH50 (total hemolytic complement)	Low; tests the whole classical pathway
ESR, CRP	Raised (nonspecific)
CBC	Leukopenia or mild leukocytosis
Urinalysis	Mild proteinuria; check it even in well-appearing patients
Creatinine	May rise; usually returns to baseline within days to weeks
Skin biopsy	Typically leukocytoclastic vasculitis (only a mild perivascular infiltrate in the leukopenic NIH patients); immunofluorescence often shows IgM, C3, IgE or IgA in dermal vessel walls
Hepatitis B screen, EBV heterophile test	When infection is a possible mimic

What the complement pattern tells you:

Complement pattern	Think of	Mechanism
Low C3 and low C4 (low CH50)	Serum sickness; active SLE	Immune complexes consume the classical pathway
Low C3, C4 usually normal	Post-streptococcal glomerulonephritis (C3 recovers within 6–8 weeks)	Alternative-pathway activation
Normal C3 and C4	Serum sickness–like reaction, anaphylaxis, DRESS	No complement-consuming immune complexes

Other mimics: viral exanthems, acute rheumatic fever, Kawasaki disease, meningococcemia, systemic juvenile idiopathic arthritis, Lyme disease and IgA vasculitis.

Management

Stop the offending agent and avoid it in the future. If it is potentially life-saving and cannot be stopped, such as antithymocyte globulin for aplastic anemia, reduce exposure where possible.
Mild to moderate symptoms: H1 antihistamines for itch and hives, NSAIDs for joint pain and fever. The rash and itching should stop progressing within about 48 hours.
Severe symptoms: a short course of systemic glucocorticoids (StatPearls suggests 7–10 days); after antivenom, Merck recommends H1 blockers plus a tapering course of oral corticosteroids.
Epinephrine is for anaphylaxis, not for this delayed immune complex reaction.
Consider admission for severe symptoms, multi-organ involvement or suspected infection; most children can be managed as outpatients.
Counsel avoidance of the agent by generic and brand name: re-exposure can cause a faster, more severe reaction. Avoiding structurally related drugs is debated.

Prognosis

The prognosis is excellent. Symptoms usually resolve within 1–2 weeks of stopping the agent, a raised creatinine returns to baseline within days to weeks, and long-term complications are not expected. Severe disease, recurrence or continued exposure can prolong the course.

Arthus reaction: the local type III reaction

The Arthus reaction is the local version: antigen injected into the skin of someone who already has circulating IgG forms immune complexes in the small vessels at the injection site. Painful swelling and redness begin within a few hours and peak within about 24 hours; severe cases cause local skin necrosis. After an Arthus-type reaction to a tetanus- or diphtheria-toxoid vaccine, CDC advises deferring tetanus toxoid–containing vaccines until at least 10 years after the last dose.

Feature	Arthus reaction	Serum sickness
Extent	Local, at the injection site	Systemic
Antibody	Preformed IgG already present	Made after the exposure (faster if primed)
Onset	Hours; peak by about 24 hours	1–2 weeks (days on re-exposure)
Findings	Painful swelling, erythema, possible local necrosis	Fever, rash, arthralgias, low C3 and C4
Classic trigger	Tetanus or diphtheria toxoid booster	Antivenom, antithymocyte globulin, chimeric antibodies

Gell and Coombs hypersensitivity types I–IV

Mnemonic: ACID, for Anaphylactic, Cytotoxic, Immune complex, Delayed. Types I–III are antibody-mediated; type IV is T cell–mediated.

Type	Mechanism	Timing	Classic examples
I Immediate	Allergen cross-links IgE on mast cells and basophils; histamine, tryptase, leukotrienes	Minutes (late phase: hours)	Anaphylaxis, allergic asthma, allergic rhinitis, urticaria and angioedema; food, venom, latex and beta-lactam allergy
II Cytotoxic	IgG or IgM against cell-surface or matrix antigens; complement lysis, opsonization, ADCC, receptor stimulation or blockade	Depends on the target	Autoimmune hemolytic anemia, transfusion reactions, ITP, anti-GBM disease (Goodpasture), Graves disease, myasthenia gravis, pemphigus vulgaris, acute rheumatic fever, hyperacute rejection
III Immune complex	Antigen–antibody complexes deposit, fix complement and recruit neutrophils	Hours (Arthus) to 1–2 weeks (serum sickness)	Serum sickness, Arthus reaction, SLE, post-streptococcal GN, polyarteritis nodosa (hepatitis B), IgA vasculitis, cryoglobulinemia, acute hypersensitivity pneumonitis
IV Delayed	Sensitized T cells: Th1 cytokines activate macrophages; CD8 cells kill directly; no antibody	48–72 hours, sometimes weeks	Contact dermatitis (poison ivy, nickel), tuberculin skin test, SJS/TEN, DRESS, acute and chronic transplant rejection, granulomas (tuberculosis, sarcoidosis), chronic hypersensitivity pneumonitis

Drill each type with the type I, type II, type III and type IV question breakdowns.

How USMLE tests serum sickness

Stems hinge on timing (see the timing table) and on complement:

Condition	Timing	Separating clues	Complement	Mechanism
Serum sickness	1–2 weeks	Fever, rash, arthralgias after a foreign protein; ± proteinuria	Low C3 and C4	Type III, systemic
SSLR	Days into a course, often the second	Child on cefaclor or another beta-lactam	Normal	Not immune complex
Anaphylaxis	Minutes	Hives, wheeze, hypotension; no arthritis	Normal	Type I (IgE)
Arthus reaction	Hours; peak by 24 hours	Painful local swelling at a booster site	Not the clue	Type III, local
DRESS	2–8 weeks	Eosinophilia (80–95%), facial edema (about 70%), organ involvement; anticonvulsants, allopurinol	Normal	Type IV
SJS/TEN	After a new drug, with a flu-like prodrome	Mucosal erosions (about 90%), skin detachment	Not the clue	Type IV
Post-streptococcal GN	Usually 1–3 weeks after strep throat or skin infection (up to 6 weeks)	Cola-colored urine, edema, hypertension; kidney-focused	Low C3, C4 usually normal	Type III, kidney

Traps to avoid:

Epinephrine is the wrong "next step" unless the patient is in anaphylaxis; stopping the trigger is right.
Complement separates the look-alikes: low C3 and C4 mean immune complexes; normal complement fits SSLR, type I or type IV reactions.

Worked examples

Vignette 1. A 42-year-old man receives ovine Fab antivenom for a rattlesnake bite. Nine days later he has a temperature of 39°C, itchy hives on his trunk, aching wrists, knees and ankles, and tender inguinal lymph nodes; his mouth and eyes are normal. Urinalysis shows 1+ protein, and C3 and C4 are low. What is the mechanism, and how should he be treated?

Answer: Serum sickness, a type III reaction: IgG against sheep protein forms complexes with antivenom still in the circulation, which deposit in vessels and consume complement. Treat with an H1 antihistamine plus a tapering course of oral glucocorticoids, the regimen Merck recommends for serum sickness after antivenom.

Reasoning: A 9-day delay fits a primary antibody response, low C3 and C4 show consumption, and spared mucosa argues against SJS/TEN.

Vignette 2. A 4-year-old girl is on day 5 of her second course of cefaclor for otitis media. She develops an itchy rash with target-like lesions, a low-grade fever and swollen, painful ankles, and she refuses to walk. C3, C4 and urinalysis are normal. What is the diagnosis?

Answer: Serum sickness–like reaction.

Reasoning: Cefaclor SSLRs are more common in children and during or after a second course, and there are no circulating immune complexes, so complement and urine are normal. Stop the drug; symptoms usually subside within a few days.

Vignette 3. A 30-year-old woman had a tetanus booster 3 years ago, but her records are unavailable when she presents with a dirty wound, so she is given Td. Six hours later her upper arm is red, swollen and painful around the injection site, with no fever or rash elsewhere. What explains this?

Answer: An Arthus reaction: injected toxoid meets preformed IgG, forming immune complexes in local vessels. Onset within hours and a purely local reaction rule out serum sickness (systemic, 1–2 weeks) and anaphylaxis (systemic, minutes).

Key takeaways

Serum sickness is a systemic type III reaction: immune complexes formed in antigen excess deposit in vessels and consume complement, so C3, C4 and CH50 are low.
Timing: 1–2 weeks after a first exposure, 1–7 days after a re-exposure; minutes means type I, and hours at an injection site means Arthus.
Triad: fever, rash (urticarial, morbilliform or purpuric, sometimes a serpiginous eruption along the edges of the palms and soles) and polyarthralgia; mucosa spared.
Triggers: animal antisera (antivenoms, antithymocyte globulin), chimeric antibodies (rituximab, infliximab) and some drugs.
SSLR (classically cefaclor in children) looks the same but has normal complement.
Treatment: stop the trigger; antihistamines and NSAIDs; glucocorticoids if severe. Most cases resolve within 1–2 weeks.